ALBPS.PA stock falls ahead of earnings: key metrics and forecast ahead of 23 Feb 2026

ALBPS.PA stock trades at €0.0548 intraday and is down 5.52% as investors position before Biophytis S.A.’s earnings release on 23 Feb 2026. The Paris-listed biotech (EURONEXT, Europe) has a market cap of €1,321,831.00 and posted EPS -0.34 last reported. With low liquidity and a 50-day average price of €0.07, the stock shows elevated volatility. This earnings spotlight focuses on catalysts, key ratios, Meyka AI grading and a model forecast to frame risk and opportunity ahead of the report.

Earnings calendar and near-term catalyst

Biophytis S.A. will announce quarterly results on 23 Feb 2026, a clear intraday catalyst for ALBPS.PA stock. Market attention will centre on clinical updates for Sarconeos (BIO101) and cash runway commentary. Guidance and cash-burn figures typically drive big intraday moves in small biotech names like ALBPS.PA.

Key financials and valuation metrics for ALBPS.PA stock

At €0.05 intraday (rounded), ALBPS.PA shows PE -0.17 and EPS -0.34, reflecting persistent losses. The company reports cash per share €0.06, current ratio 0.35, and enterprise value of €7,886,831.00, signalling tight liquidity. Year high is €0.40 and year low €0.055, underscoring wide historical swings for this biotechnology developer.

Technical and trading snapshot

Volume today is 542,809 versus average volume 695,656, leaving relative volume at 0.21, which can mute price moves. Momentum indicators show an RSI of 41.87 and MFI 9.02 indicating oversold conditions. Short-term moving averages sit below the 50-day average of €0.07, consistent with a recent downtrend for ALBPS.PA stock.

Meyka AI grade and model forecast for ALBPS.PA stock

Meyka AI rates ALBPS.PA with a score out of 100: 70.97 (B+, BUY). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects €2.20497 over the yearly horizon. Against the current price €0.0548, that implies an implied upside of 3924.51%. Forecasts are model-based projections and not guarantees.

Catalysts and risks affecting ALBPS.PA stock

Positive catalysts include favourable clinical data for BIO101 or Macuneos and clearer financing plans. Major risks are cash constraints, trial setbacks and low liquidity that can amplify moves. Regulatory readouts and partnership updates remain binary events that will swing ALBPS.PA stock intraday around the earnings release.

Practical price targets and trading scenarios

We set a near-term base case 12-month price target of €0.10 and a bullish scenario target of €0.50. A conservative bear scenario is €0.03 if trials disappoint or dilutive financing occurs. Use tight risk controls: average daily volume under 700,000 shares can widen spreads and raise execution costs for ALBPS.PA stock.

Final Thoughts

ALBPS.PA stock is highly speculative ahead of earnings on 23 Feb 2026. The company trades at €0.0548 with negative earnings and thin liquidity. Our Meyka AI grade is B+ (70.97) and highlights both clinical upside and sizable execution risk. Meyka AI’s forecast model projects €2.20497 over a yearly horizon, implying an upside of roughly 3924.51% versus the current price €0.0548. That projection reflects model drivers, not a guaranteed outcome. For traders, the immediate play is event-driven: watch the earnings readout, trial updates, and financing commentary. For investors, balance potential clinical upside against weak cash metrics, a current ratio of 0.35, and negative operating cash flow. If you hold ALBPS.PA stock, consider a strict position size and defined stop. Meyka AI, an AI-powered market analysis platform, flags the stock as a binary biotech with asymmetric outcomes and recommends research before acting. Sources: Reuters: Biophytis SA company page and Investing.com: Biophytis compare.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.